BEARINGPOINT
20.6.2022 10:49:12 CEST | Business Wire | Press release
Management and technology consultancy BearingPoint has acquired I Care, a consultancy firm specializing in sustainability strategy development and environmental transition. With the integration, BearingPoint expands its offerings in the area of sustainability consulting and accelerates growth in its key consulting markets.
Established in 2008, I Care has more than 80 employees in France and Brazil and offers consulting services to public organizations, NGOs, private companies and financial institutions to respond to the risks and opportunities of the environmental transition. I Care distinguished itself by developing innovative methods and tools to quantify the performance of actors in the area of low-carbon transition and biodiversity footprint. By hybridizing scientific and strategy consulting skills, I Care has positioned itself as a key player in helping organizations define and implement environmental strategies.
“I Care’s capabilities and service offerings match perfectly with the needs of our clients in Europe. Moreover, we share the same culture of an entrepreneurial, holistic mindset and are trusted advisors for our clients. Together we look forward to becoming the key player in sustainable and environmental transformation consulting in France and entering selected markets internationally,” says Axelle Paquer, Regional Leader for France, Belgium, Luxemburg and Africa at BearingPoint.
BearingPoint , with more than 1,000 employees in France and 4,300 in Europe, has had a dedicated practice in sustainable development since 2010. This includes support for companies and public organizations in strategy, digital responsibility and the calculation of carbon emissions with its emissions calculator solution. BearingPoint is thus strengthening its ability to support clients in all aspects of their sustainable development strategies.
“I Care has a strong reputation for helping clients drive sustainability strategies and environmental transformation. Its proven practice and methodology combined with our transformation and digitalization capabilities will allow us to develop compelling new value propositions for our existing client portfolio in Europe, the US and China,” says Kiumars Hamidian, Managing Partner BearingPoint.
“Joining BearingPoint will enable I Care to accelerate our growth plans within a range of industry sectors in France and open the doors into more markets internationally. We are keen to leverage BearingPoint’s wider capabilities, notably in services such as emissions calculation and digital transformation, to benefit our existing client base. Becoming part of a leading international consulting organization opens up an opportunity to further increase our impact on society. ” says Guillaume Neveux, founder and CEO at I Care.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information about BearingPoint, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
About I Care
I Care is a leading consulting company in the environmental field. Since 2008, I Care assists companies, financial institutions, and public organizations in their transition towards a low environmental impact society.
Combining expertise in strategy, finance, project management, and technical skills, its ambition is to provide clients with global solutions to their environmental challenges with the objective of moving to a sustainable economy. Thanks to its multidisciplinary approach between environmental expertises, consulting, research, the private, and public sectors, I Care has a wide range of skills providing a comprehensive response to the diverse needs in the field of sustainable development.
For more information about I Care, please visit:
Homepage: https://www.i-care-consult.com/
LinkedIn: https://www.linkedin.com/company/i-care-environnement/
Twitter: https://twitter.com/I_Care_Consult
View source version on businesswire.com: https://www.businesswire.com/news/home/20220620005150/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom